glecaprevir/pibrentasvir vs valsartan
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of glecaprevir/pibrentasvir and valsartan. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
7.5 Drugs with No Observed Clinically Significant Interactions with MAVYRET No dose adjustment is required when MAVYRET is coadministered with the following medications: abacavir, amlodipine, caffeine, dextromethorphan, dolutegravir, elvitegravir/ cobicistat, emtricitabine, ethinyl estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam, norethindrone or other progestin-only contraceptives, omeprazole, raltegravir, rilpivirine, sofosbuvir, tacrolimus, tenofovir alafenamide, tenofovir disoproxil fumarate, tolbutamide, and valsartan.
Mavyret
Diovan
Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.
Entresto is a medicine that combines two drugs to help adults and children with heart failure. It can lower the risk of death and hospitalization.
Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. It can be used in people without cirrhosis or with compensated cirrhosis. Mavyret can also treat genotype 1 in people who have already been treated with certain other HCV medicines.
Entresto is used to treat heart failure in adults and children aged one year and older. It helps people whose hearts don't pump blood well enough. It can reduce hospital visits and the risk of death from heart problems.
Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.
Entresto works by blocking two substances in your body that can worsen heart failure. One substance is neprilysin, and the other is angiotensin II. By blocking these, Entresto helps your heart pump blood more easily and reduces strain.
- • Headache
- • Feeling tired
- • Nausea
- • Low blood pressure
- • High potassium levels in your blood
- • Cough
- • Dizziness
- • Kidney problems
- Feeling tired 2,561
- Headache 2,203
- Nausea 1,125
- Itching 653
- Diarrhea 477
- Fatigue 5,474
- Dyspnoea 5,250
- Dizziness 5,249
- Nausea 5,162
- Diarrhoea 4,578
Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.
Entresto can harm your unborn baby, even causing death. If you are pregnant or become pregnant, stop taking Entresto right away and tell your doctor.
It is not known if Mavyret will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Mavyret passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Mavyret.
Entresto can cause serious harm or death to an unborn baby. Do not take this medicine if you are pregnant. Breastfeeding is not recommended while taking Entresto.
Also Compare, Nearby Drugs
Compare valsartan with
How to Read This glecaprevir/pibrentasvir vs valsartan Comparison
glecaprevir/pibrentasvir is classified in the NS3/4A/NS5A Inhibitor (HCV) drug class, while valsartan sits within the Angiotensin II Receptor Blocker (ARB) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, glecaprevir/pibrentasvir has 7,019 submissions while valsartan has 25,713. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to there is no significant interaction between these two drugs that would affect how they work.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for glecaprevir/pibrentasvir or valsartan.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.